Genenta Science S.p.A.

Develops cell & gene therapies using engineered stem cells to treat solid tumors.

GNTA | NDAQ

Overview

Corporate Details

ISIN(s):: US36870W1009
LEI:
Country:: United States of America
Address:: OLGETTINA, NO. 58, 20132 MILAN
Website:: https://www.genenta.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Genenta Science S.p.A. is a clinical-stage immuno-oncology company developing proprietary cell and gene therapies for the treatment of solid tumors. The company's technology is centered on engineering a patient's own hematopoietic stem cells using a lentiviral vector to combat cancer. Its lead candidate, Temferon, is designed to make tumors visible to the immune system by reprogramming the tumor microenvironment and breaking immune tolerance. Genenta has completed a Phase 1 clinical trial in Glioblastoma Multiforme and has initiated a Phase 1/2a study in metastatic Renal Cell Carcinoma. The treatments are designed as one-time monotherapies that also have the potential to be used in combination to enhance the efficacy of other therapeutics, such as immune checkpoint inhibitors.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Genenta Science S.p.A. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Genenta Science S.p.A.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for Genenta Science S.p.A. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
Entero Therapeutics, Inc. Develops targeted oral therapies for a range of gastrointestinal (GI) diseases.	United States of America	ENTO
Entrada Therapeutics, Inc. Developing intracellular therapeutics for rare neuromuscular diseases via its EEV™ platform.	United States of America	TRDA
ENZYCHEM LIFESCIENCES CORPORATION Develops novel therapeutics and APIs for oncology, inflammation, and respiratory diseases.	South Korea	183490
Enzymatica AB Develops medical devices with patented enzyme technology to treat upper respiratory infections.	Sweden	ENZY
Epi Biotech Co., Ltd. Developing alopecia therapies, skin regeneration products, and preclinical CRO services.	South Korea	446440
EQL Pharma AB Develops and sells cost-efficient niche generic medicines for the Nordic healthcare market.	Sweden	EQL
Equillium, Inc. Clinical-stage biotech creating therapies for severe autoimmune and inflammatory disorders.	United States of America	EQ
Erasca, Inc. Clinical-stage oncology company developing therapies targeting the RAS/MAPK pathway in cancer.	United States of America	ERAS
Ernexa Therapeutics Inc. Developing targeted, off-the-shelf cell therapies for cancer and autoimmune diseases.	United States of America	ERNA
ERYTECH Pharma S.A. Developing phage therapies to combat antibiotic-resistant bacterial infections.	France	ERYP